Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis

Among patients with gastric cancer and peritoneal metastasis, does adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improve overall survival compared with intravenous paclitaxel plus S-1?In this randomized clinical trial that included 222 patients with gastric cancer with peritoneal metastasis, intraperitoneal and intravenous paclitaxel plus oral S-1 resulted in significantly longer overall survival than intravenous paclitaxel plus S-1 alone (19.4 vs 13.9 months) without increasing grade 3 or 4 adverse events.The findings of this randomized clinical trial potentially provide an encouraging signal that intraperitoneal paclitaxel may enhance first-line treatment of gastric cancer with peritoneal metastasis.

Corresponding Authors: Zhenggang Zhu, MD, PhD, Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Huangpu District, Shanghai 200025, China (zzg1954@hotmail.com); Kai Yin, MD, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Naval Medical University, 168 Changhai Road, Yangpu District, Shanghai 200433, China (kyin67@smmu.edu.cn).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.